DOCSLIB.ORG

Singapore Welcomes Sir David Lane!

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Singapore Welcomes Sir David Lane! www.asiabiotech.com People Singapore Welcomes Sir David Lane! ingapore has successfully wooed a top-notch cancer researcher to head the Institute of Molecular and Cell Biology (IMCB), a member of the country’s main life sciences Sbody, the Agency for Science, Techology and Research (A*Star). Professor Sir David Lane hails from Scotland’s University of Dundee, a world-renowned institution highly acclaimed for its biomedical and life sciences research. Practically a household name in the field of cancer, Prof. Lane is best known for his 1979 breakthrough discovery of the landmark cancer gene — the p53 cancer gene. Mutations of this tumor suppressor gene are found in more than half of all human cancers. This finding has pointed the way for other cancer researchers to understand and manipulate the cellular processes in cancer. As of August 2004, Prof. Lane officially assumes the role of executive director of IMCB. His stint in Singapore is a two-year sabbatical, during which he will maintain his links in Britain. Prof. Lane sees this new appointment as a research opportunity to translate basic biological science into new technologies and new medicines in an integrated environment. More on Professor Lane… “It is a mark of David Lane’s distinction that he has been asked to become IMCB’s executive Professor Lane founded biopharmaceutical director. He has long been one of the most company Cyclacel in September 1996. Until May of 2004, he was the company’s Chief respected scientists and is a valued member of Scientific Officer and continues to Chair the the scientific executive board at Cancer Scientific Advisory Board. Research UK. Our close association with him Professor Lane is Professor of Molecular will continue both in Singapore and Dundee.” Oncology and Director of the CRC Cell Transformation Research Group in the Professor Robert Souhami Department of Biochemistry at the University of Dundee. He has previously held the positions Executive Director of Clinical Affairs of Principal Scientist at the Imperial Cancer Cancer Research, UK (World’s largest independent organization Research Fund and Lecturer in Biochemistry at dedicated to cancer research) Imperial College. APBN • Vol. 9 • No. 5 • 2005 191 www.asiabiotech.com People Professor Lane holds a PhD from University College London, and did his postdoctoral work at Imperial Cancer Research Fund in London and at Cold Spring Harbor Laboratory in New York. He is a Fellow of the Royal Society and a member of the European Molecular Biology Organization. In 2000, Prof. Lane was knighted for his contributions to cancer research, and was named by Science magazine as the world’s seventh most-cited scientist. He has won numerous international awards, including the Paul Ehrlich Prize, the Joseph Steiner Prize, the CR Brupbacher Foundation Prize, the Medal of the Swedish Society of Oncology, the Yvette Mayent Prize, the Mayenberg Preis, the Silvanus Thompson Medal, the Medal of the Society of Chemical Industry and has been named a Howard Hughes Scholar. He has authored approximately 250 publications and patents. About Cyclacel Cyclacel is a biopharmaceutical company that designs and develops small molecule drugs that act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation. Cyclacel’s discovery engines integrate cell cycle biology expertise with a large library of gene-based targets, RNAi functional genomics, chemogenomics and clinical biomarker technologies to deliver new drugs. The company has nine research and development programs underway. Most advanced is CYC202, an oral Cyclin Dependent Kinase (CDK) inhibitor, in Phase II trials for lung cancer and hematological malignancies. CYC202 has completed Phase I trials and is also being explored for use in glomerulonephritis, an inflammatory disease associated with kidney cell proliferation. CYC682, an oral nucleoside analogue, in Phase Ib trials was shown in preclinical tests to have superior efficacy to gemcitabine. Cyclacel has entered into corporate alliances with AstraZeneca, CV Therapeutics, GlaxoSmithKline, Lorus and Sankyo, all in the oncology field. Cyclacel is the first European university spin-out company to have raised more than US$100 million in private equity. Contact Details: Cyclacel Limited Address: James Lindsay Place, Dundee Technopole Dundee DD1 5JJ, United Kingdom Tel: +44 1382 206 062 Fax: +44 1382 206 067 Email: [email protected] URL: www.cyclacel.com 192 APBN • Vol. 9 • No. 5 • 2005.
Load more

Recommended publications
  • Modelling Malignant Progression with a Finite State Machine Supports a Two Checkpoint Theory of Cancer
    COVER STORY BioDiscovery Man of Science: Celebrating Professor Sir David Lane’s th 60 anniversary Nikolai Zhelev School of Contemporary Sciences, Kydd Building, 40 Bell Street, University of Abertay Dundee, Dundee, DD1 1HG, Scotland, UK Abstract th This article is devoted to the 60 anniversary of Professor Sir David Lane and summarises his renowned research career and scientific and business achievements to date. Professor Lane is one of the world’s foremost cancer biologists with more than 350 publications in the world leading science journals and was the second most highly cited UK-based scientist in the 1990’s. Sir David is best known for the discovery of the p53 protein which he termed “the guardian of the genome” due to its vital role in the defence against cancer. A decade later p53 was named “molecule of the year” by the scientific journal Science. Professor Lane has won many international prizes and awards for his outstanding work in the field of cancer research and drug development. th Citation: Zhelev N. Man of Science: Celebrating Professor Sir David Lane’s 60 anniversary. Biodiscovery 2012; 1: 5. DOI: 10.7750/BioDiscovery.2012.1.5 Copyright: © 2012 Zhelev. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, provided the original authors and source are credited. Received: 1 June 2012; Accepted: 25 June 2012; Available online /Published: 1 July 2012 Corresponding Author: Nikolai Zhelev, e-mail: [email protected] Conflict of Interests: No potential conflict of interest was disclosed. Born in 1952 David, the son of an accountant completed his undergraduate and PhD in University College London.
    [Show full text]
  • Communicating Biochemistry: Meetings and Events
    © The Authors. Volume compilation © 2011 Portland Press Limited Chapter 3 Communicating Biochemistry: Meetings and Events Ian Dransfield and Brian Beechey Scientific conferences organized by the Biochemical Society represent a key facet of activity throughout the Society’s history and remain central to the present mission of promoting the advancement of molecular biosciences. Importantly, scientific conferences are an important means of communicating research findings, establishing collaborations and, critically, a means of cementing the community of biochemical scientists together. However, in the past 25 years, we have seen major changes to the way in which science is communicated and also in the way that scientists interact and establish collabo- rations. For example, the ability to show videos, “fly through” molecular structures or show time-lapse or real-time movies of molecular events within cells has had a very positive impact on conveying difficult concepts in presentations. However, increased pressures on researchers to obtain/maintain funding can mean that there is a general reluctance to present novel, unpublished data. In addition, the development of email and electronic access to scientific journals has dramatically altered the potential for communi- cation and accessibility of information, perhaps reducing the necessity of attending meetings to make new contacts and to hear exciting new science. The Biochemical Society has responded to these challenges by progressive development of the meetings format to better match the
    [Show full text]
  • 8Th INTERNATIONAL MUTANT P53 WORKSHOP & P53 ISOFORMS
    Major sponsors LYON CATHOLIC UNIVERSITY Corporate sponsors 8th INTERNATIONAL MUTANT P53 WORKSHOP & P53 ISOFORMS Other sponsors by ESSEN BIOSCIENCE LYON, 15-18 MAY 2019 Crédits photos : T. Bianchin LYON CATHOLIC UNIVERSITY mutantp53workshop.com Dear Friends and Colleagues, On behalf of the scientific and organizing committees, it is my pleasure to welcome you in Lyon for the 8th Mutant p53 Workshop. 18 years after the first workshop in 2001, it is great to bring this meeting back to Lyon. Since then, the workshop has become a major event for the p53 community, building up on a series of successful editions such as the most recent one held in Melbourne in October 2016. This workshop comes at a very special time for p53 community. Indeed, the Li-Fraumeni syndrome was first described in 1969, p53 itself came into being in 1979 and mutant p53 was recognized as a majorevent in cancer in 1989, followed by the discovery of germline mutations in LFS. We are thus celebrating a triple anniversary highlighting several decades of huge progress in understanding the multiple facets of this fascinating protein. The workshop is a great opportunity to look forward Editorial into the promises of the next decades. We are now at a stage where several drugs targeting p53 are entering the clinics. Mutant p53 is also revealing itself as a potential neoantigen for targeted immunotherapies. Much knowledge still needs to be gained but the road lies wide open for decades of successful translation to cancer care. Much of these advances owe to the beautiful work of the mutant p53 community – Your work.
    [Show full text]
  • Fmedsci., FUCL CURRICULUM VITAE Professor Sir David Lane Is
    Professor Sir David Lane FRS, FRSE, FRCPath., FRCS (Edinburgh), FmedSci., FUCL CURRICULUM VITAE Professor Sir David Lane is the Director of the Cancer Research UK Transformation Research Group at the University of Dundee, where he leads research teams studying Human Tumour suppressor gene function. He is also Chief Scientist of Agency for Science, Technology and Research (A*STAR). Sir David completed undergraduate and postgraduate degrees at University College London where he studied auto- immunity under the supervision of Avrion Mitchison. He carried out Post Doctoral Research first at the Imperial Cancer Research Fund in London with Lionel Crawford and then at the Cold Spring Harbor Labs in New York with Jo Sambrook. On returning to the UK, Sir David set up his own laboratory with CRC funding at Imperial College, London, then moving to the ICRF laboratories at Clare Hall before moving in 1990 to Dundee to help establish the CRC laboratories there. Sir David has published more than 350 research articles that have been citied over 39,000 times and is internationally recognised for his original discovery of the p53 protein SV40 T antigen complex and for his many subsequent contributions to the p53 field. The p53 gene is the most frequently altered gene in human cancer with more than half of all cancers having mutant p53. He is co-author with Ed Harlow of the most successful practical guide to the use of immunochemical methods. The "Antibodies" manual has sold over 40,000 copies. Sir David is a member of EMBO, and a Fellow of the Royal Society, the UK's premier Academy.
    [Show full text]